A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 83-88

  Lee, Dae Ho ^a   Kim, Heung Tae ^b   Han, Ji Youn ^b   Lee, Sung Young ^b   Yoon, Sung Jin ^b   Kim, Hyae Young ^b   Lee, Jin Soo ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Cisplatin; Esophageal squamous cell carcinoma; Irinotecan; Modified schedule

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE;

EID: 34848882552     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0450-7     Document Type: Article

References (29)

1. Stewart BW, Kleihues P (2003) World cancer report. IARC Press Lyon, France
2. Ilson DH (2003) Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525-532
3. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091
4. Seymour MT, Dent JT, Papamichael D, Wilson G, Cresswell H, Slevin ML (1999) Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. Ann Oncol 10:1329-1333
5. Lee J, Im Y, Kang J, E Nam, Lee S, Park J, Park Y, Kang W, Park K (2005) Phase II study of capecitabine and cisplatin as first-line therapy in patients with recurrent or metastatic esophageal carcinoma. J Clin Oncol 2005 ASCO Ann Meet Proc 23(16S):4221
6. Conroy T, Etienne PL, Adenis A, Wagener DJ, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 14:164-170
7. Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, Wolf KJ, Riecken EO, Zeitz M, Scherubl H (2003) A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic carcinoma. Int J Colorectal Dis 18:330-334
8. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955-959
9. Ilson DH, Saltz L, Enzinger P, Huang Y, Komblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP (1999) A phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270-3275
10. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K (2001) Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92:269-275
11. World Health Organization (1979) Handbook for REPORTING RESULTS OF CANCER TREATMENt (WHO Offset Publication No. 48). World Health Organization, Geneva
12. National Cancer Institute. (1999) The revised common toxicity criteria:Version 2.0. CTEP Website. http://www.ctep.info.nih.gov (30 September 2006, date last assessed)
13. Simon R. (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trial 10:1-10
14. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288
15. Ilson DH (2004) Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 18(Suppl 14):22-25
16. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
17. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Buqat R (2004) Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15:1773-1781
18. Han JY, Lim HS, Lee DH, Ju SY, Lee SY, Kim HY, Park YH, Park CG, Lee JS (2006) Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 106:873-880
19. Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargen D, Goldberg RM (2002) A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 32:115-123
20. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C (2003) Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 89:630-633
21. Ajani JA (1994) Contribution of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 21:474-482
22. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
23. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216-1220
24. Ilson DH, Banis M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD (2003) Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21:2926-2932
25. Ilson DH, Minsky B, Kelson D (2002) Irinotecan, cisplatin, and radiation in esophageal cancer. Oncology (Williston Park) 16(suppl 5):11-15
26. Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'Homme S, Paillot B (2006) Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer 95:705-709
27. Visbal AL, Darling G, Wong R, Guindi M, Hornby J, Feld R, Ringash J, Keshavjee S, Chen E, Brierly J, Knox J (2006) Phase II trial of preoperative (POP) irinotecan (I) + cisplatin (C) and radiotherapy for esophageal cancer. J Clin Oncol 2006 ASCO Ann Meet Proc 24(18S):4056
28. Enzinger PC, Yock T, Suh W, Fidias P, Mamon H, Choi N, Lehman N, Lawrence C, Lynch T, Fuchs C (2006) Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol 2006 ASCO Ann Meet Proc 24(18S):4064
29. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206